QUICK LINKS
MAIN MENU
CONNECT WITH US

Clinical Trial Details

Title
A Randomized, Double-Blind, Placebo-controlled, Parallel-group Study to Evaluate the Effect of Long-term Treatment with BELVIQ (lorcaserin HCI) on the Incidence of Major Adverse Cardiovascular Events and Conversion to Type 2 Diabetes Mellitus in Obese and Overweight Subjects with Cardiovascular Disease or Multiple Cardiovascular Risk Factors CAMELLIA
Study Purpose
The main purpose of this research study is to assess whether lorcaserin HCl (brand name BELVIQ®) affects the risk of developing cardiovascular diseases in men and women at higher risk of developing these diseases.
Study Plan
Subjects will be randomized to study drug or placebo.
Investigators

Principal Investigator
Dominick J. Angiolillo, M.D., Ph.D., FACC
Medicine

Sub Investigator
Theodore A. Bass, M.D.
Medicine

Sub Investigator
Martin "M" Zenni, M.D.
Medicine

Meeting Schedule & Submission Deadlines

Resources

News & Announcements

Spotlighting innovation and discovery on campus - Thumb

Spotlighting innovation and discovery on campus

5/30/2018

Residents, faculty and staff share their latest research, garner awards during annual Celebration of Research event Nipa Shah, MD, se... [full story]

Aging studies center officially opens  - Thumb

Aging studies center officially opens

5/16/2018

JAX-ASCENT to focus on research targeting adults 60 and older    The clipping of a blue ribbon Friday, May 11, marked t... [full story]

A culturally sensitive approach to weight loss - Thumb

A culturally sensitive approach to weight loss

3/16/2018

Black women participants are sought for a $2.1 million research project targeting obesity UF Health researchers are looking for primar... [full story]

Upcoming Events

There are currently no events to display. Check back soon!